Opportunity Information: Apply for RFA MH 19 510
This grant opportunity, titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R01 Clinical Trial Optional)," is a National Institutes of Health (NIH) funding announcement designed to support research that explains why neuropsychiatric symptoms occur in people living with Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD). The central focus is on mechanism: the studies funded under this announcement are expected to move beyond simply describing symptoms and instead clarify the underlying biobehavioral and neurobiological pathways that lead to common and burdensome psychiatric and behavioral changes in dementia. The intent is that stronger mechanistic knowledge will point to new intervention targets to reduce symptom burden and caregiver strain, or help identify better prevention strategies that could limit the emergence or progression of these symptoms in the first place.
The opportunity uses the NIH R01 mechanism, which is the standard research project grant meant for well-justified, hypothesis-driven programs of work. The "Clinical Trial Optional" designation means applicants may propose either non-clinical trial mechanistic studies or studies that include a clinical trial component, as long as the work fits the overall purpose of explaining mechanisms related to neuropsychiatric symptoms in AD/ADRD. In practical terms, this allows a wide range of approaches, from observational and laboratory-based human studies to intervention studies that test mechanistically grounded targets, provided the research is framed around understanding the pathways that produce symptoms such as agitation, depression, anxiety, apathy, psychosis, sleep disturbances, irritability, or related behavioral and emotional changes that often accompany dementia.
Administratively, this is a discretionary grant opportunity in the health funding category, funded by NIH under CFDA 93.242, and identified as Funding Opportunity Number RFA MH 19 510. The listing indicates an original application due date of March 19, 2019, and a creation date of September 18, 2018, which places it as a time-limited solicitation rather than an always-open program announcement. While the record does not provide an award ceiling or expected number of awards, the key takeaway is that it was a targeted request for applications intended to stimulate focused, mechanistic research on NPS in dementia rather than general Alzheimers research.
Eligibility is broad and intentionally inclusive. In addition to typical academic and research organizations, eligible applicants include state, county, city, and special district governments; independent school districts; public and state controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education where relevant); for-profit organizations (other than small businesses); and small businesses. The announcement also explicitly highlights additional eligible applicant types that NIH encourages to apply, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). Taken together, the eligibility language signals an interest in supporting diverse institutions and settings, which can be important for recruiting representative participant samples and studying symptom mechanisms across different populations and care environments.
Overall, the purpose of the FOA is to accelerate progress on a major unmet need in dementia care by funding research that clarifies how and why neuropsychiatric symptoms arise in AD/ADRD. By prioritizing mechanistic insights that connect biology, behavior, and lived experience, the program is meant to lay groundwork for more precise and effective ways to prevent, detect, and treat these symptoms, ultimately reducing distress for patients and easing the burden on caregivers and health systems.Apply for RFA MH 19 510
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2018-09-18.
- Applicants must submit their applications by 2019-03-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R01 Clinical Trial Optional)
What is the title of this grant opportunity?
The opportunity is titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R01 Clinical Trial Optional)."
Which agency is offering this funding opportunity?
This is a National Institutes of Health (NIH) funding announcement.
What is the main purpose of the funding opportunity?
The purpose is to support research that explains why neuropsychiatric symptoms occur in people living with Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD), with an emphasis on identifying the mechanisms that drive these symptoms.
What does the funding announcement mean by "mechanism"?
Mechanism refers to the underlying biobehavioral and neurobiological pathways that lead to common psychiatric and behavioral changes in dementia. Projects are expected to move beyond describing symptoms and instead clarify how and why the symptoms arise.
What kinds of symptoms are in scope for this program?
The announcement points to common and burdensome neuropsychiatric symptoms such as agitation, depression, anxiety, apathy, psychosis, sleep disturbances, irritability, and related behavioral and emotional changes that often accompany dementia.
Is this opportunity focused on Alzheimers disease only?
No. The focus includes Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD).
What is the expected outcome or impact of the research funded under this FOA?
The intent is that stronger mechanistic knowledge will point to new intervention targets to reduce symptom burden and caregiver strain, and/or help identify prevention strategies that could limit the emergence or progression of neuropsychiatric symptoms.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R01 mechanism, which is a standard research project grant intended for well-justified, hypothesis-driven programs of research.
What does "Clinical Trial Optional" mean for applicants?
"Clinical Trial Optional" means applicants may propose either mechanistic studies that do not include a clinical trial or studies that include a clinical trial component, as long as the work fits the overall purpose of explaining mechanisms related to neuropsychiatric symptoms in AD/ADRD.
Are clinical trials required?
No. A clinical trial component may be included, but it is not required under the "Clinical Trial Optional" designation.
What types of research approaches are allowed under this FOA?
The opportunity allows a wide range of approaches, including observational and laboratory-based human studies, as well as intervention studies that test mechanistically grounded targets, provided the project is framed around understanding the pathways that produce neuropsychiatric symptoms in AD/ADRD.
Is this funding meant for general Alzheimers research?
No. The key emphasis is targeted, mechanistic research specifically focused on neuropsychiatric symptoms (NPS) in AD/ADRD, rather than broad Alzheimers research that is not centered on NPS mechanisms.
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number listed is RFA MH 19 510.
What is the CFDA number associated with this opportunity?
The opportunity is funded under CFDA 93.242.
What is the funding category and award type?
The listing describes this as a discretionary grant opportunity in the health funding category.
When was this opportunity created?
The creation date listed is September 18, 2018.
What was the application due date?
The listing indicates an original application due date of March 19, 2019.
Does the information provided indicate this was a time-limited solicitation?
Yes. The presence of specific creation and due dates indicates it was a time-limited request for applications rather than an always-open program announcement.
Does the provided record list an award ceiling?
No. The information provided does not include an award ceiling.
Does the provided record list the expected number of awards?
No. The information provided does not specify an expected number of awards.
Who is eligible to apply?
Eligibility is broad and includes academic and research organizations as well as many other entity types, including state, county, city, and special district governments; independent school districts; public and state controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education where relevant); for-profit organizations (other than small businesses); and small businesses.
Are U.S. territories or possessions eligible?
Yes. The announcement explicitly includes regional organizations and U.S. territories or possessions among the additional eligible applicant types NIH encourages to apply.
Are non-U.S. (foreign) organizations eligible?
Yes. The eligibility language explicitly includes non-U.S. entities (foreign organizations).
Are faith-based or community-based organizations eligible?
Yes. The announcement explicitly highlights faith-based or community-based organizations among the additional eligible applicant types NIH encourages to apply.
Are minority-serving institutions specifically encouraged to apply?
Yes. The announcement highlights that NIH encourages applications from institutions such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are federal agencies eligible to apply?
Yes. The announcement includes eligible federal agencies among the additional applicant types NIH encourages to apply.
Why does the FOA emphasize broad and inclusive eligibility?
Based on the information provided, the inclusive eligibility language signals interest in supporting diverse institutions and settings, which can matter for recruiting representative participant samples and studying symptom mechanisms across different populations and care environments.
How does this FOA connect research to caregiver outcomes?
The stated intent is that mechanistic insights will enable new intervention targets and prevention strategies that reduce symptom burden and caregiver strain, easing distress for patients and lowering burden on caregivers and health systems.
What is the central theme that applications should align with?
The central theme is explaining the mechanisms behind neuropsychiatric symptoms in AD/ADRD, linking biology, behavior, and lived experience to clarify how and why these symptoms arise.
Browse more opportunities from the same category: Health
Next opportunity: NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional)
Previous opportunity: Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 19 510
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 19 510) also looked into and applied for these:
| Funding Opportunity |
|---|
| Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed) Apply for PAR 18 923 Funding Number: PAR 18 923 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R21 Clinical Trial Optional) Apply for RFA MH 19 511 Funding Number: RFA MH 19 511 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Primary Caregiver Technical Assistance Supplements (PCTAS) (Clinical Trial Optional Admin Supp) Apply for PA 18 926 Funding Number: PA 18 926 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Technologies for HIV Behavioral and Social Science Research (R43/R44 Clinical Trial Optional) Apply for PA 18 928 Funding Number: PA 18 928 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Technologies for HIV Behavioral and Social Science Research (R41/R42 Clinical Trial Optional) Apply for PA 18 927 Funding Number: PA 18 927 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed) Apply for RFA DE 19 005 Funding Number: RFA DE 19 005 Agency: National Institutes of Health Category: Health Funding Amount: $650,000 |
| Research Centers in Minority Institutions (RCMI) (U54)- Clinical Trials Optional Apply for RFA MD 18 012 Funding Number: RFA MD 18 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01 Clinical Trial Not Allowed) Apply for PAR 18 929 Funding Number: PAR 18 929 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed) Apply for PAR 18 930 Funding Number: PAR 18 930 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional) Apply for PA 18 936 Funding Number: PA 18 936 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) Apply for PA 18 939 Funding Number: PA 18 939 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional) Apply for PA 18 937 Funding Number: PA 18 937 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical and Translational Science Award (U54 Clinical Trial Optional) Apply for PAR 18 940 Funding Number: PAR 18 940 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional) Apply for PAR 18 941 Funding Number: PAR 18 941 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Optional) Apply for PAR 18 942 Funding Number: PAR 18 942 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC) (UM1 Clinical Trial Required) Apply for RFA AI 18 047 Funding Number: RFA AI 18 047 Agency: National Institutes of Health Category: Health Funding Amount: $1,700,000 |
| Dysregulation and Proximal Risk for Suicide FOA (R01 Clinical Trial Optional) Apply for RFA MH 19 211 Funding Number: RFA MH 19 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Voluntary Family Planning for Improved Reproductive Health and Development. Apply for RFI 617 19 FAMILY PLANNING Funding Number: RFI 617 19 FAMILY PLANNING Agency: Uganda USAID-Kampala Category: Health Funding Amount: Case Dependent |
| Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required) Apply for RFA AI 18 046 Funding Number: RFA AI 18 046 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Social and Behaviour Change for Transformation (SBC4T) Apply for RFI 617 19 SBC4T Funding Number: RFI 617 19 SBC4T Agency: Uganda USAID-Kampala Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 19 510", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.